losartan has been researched along with Ventricular Dysfunction in 4 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Ventricular Dysfunction: A condition in which HEART VENTRICLES exhibit impaired function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Losartan has been proposed as a new therapeutic tool for this purpose." | 6.84 | Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial. ( Campens, L; De Backer, J; De Nobele, S; De Paepe, A; Devos, D; Muiño-Mosquera, L, 2017) |
| "Losartan has been proposed as a new therapeutic tool for this purpose." | 2.84 | Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial. ( Campens, L; De Backer, J; De Nobele, S; De Paepe, A; Devos, D; Muiño-Mosquera, L, 2017) |
| "Treatment with losartan for 3 mo had no effect on LV mass measured by echo (141+/-5 vs." | 2.69 | Losartan improves diastolic ventricular filling of hypertensive patients with diastolic dysfunction. ( Ayoub, JC; Costa, OM; de Parma, AH; Delgado, AS; Parro, A; Takakura, IT; Vitola, JV, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muiño-Mosquera, L | 1 |
| De Nobele, S | 1 |
| Devos, D | 1 |
| Campens, L | 1 |
| De Paepe, A | 1 |
| De Backer, J | 1 |
| Oliveira-Junior, SA | 1 |
| Dal Pai, M | 1 |
| Guizoni, DM | 1 |
| Torres, BP | 1 |
| Martinez, PF | 1 |
| Campos, DHS | 1 |
| Okoshi, MP | 1 |
| Okoshi, K | 1 |
| Padovani, CR | 1 |
| Cicogna, AC | 1 |
| Rosendahl, A | 1 |
| Niemann, G | 1 |
| Lange, S | 1 |
| Ahadzadeh, E | 1 |
| Krebs, C | 1 |
| Contrepas, A | 1 |
| van Goor, H | 1 |
| Wiech, T | 1 |
| Bader, M | 1 |
| Schwake, M | 1 |
| Peters, J | 1 |
| Stahl, R | 1 |
| Nguyen, G | 1 |
| Wenzel, UO | 1 |
| Ayoub, JC | 1 |
| Vitola, JV | 1 |
| Parro, A | 1 |
| Costa, OM | 1 |
| Delgado, AS | 1 |
| de Parma, AH | 1 |
| Takakura, IT | 1 |
2 trials available for losartan and Ventricular Dysfunction
| Article | Year |
|---|---|
Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Aortic Aneurysm, Thoracic; Double-Blind Method; Echo | 2017 |
Losartan improves diastolic ventricular filling of hypertensive patients with diastolic dysfunction.
Topics: Adult; Aged; Antihypertensive Agents; Echocardiography; Electrocardiography; Female; Humans; Hyperte | 1999 |
2 other studies available for losartan and Ventricular Dysfunction
| Article | Year |
|---|---|
Effects of AT1 receptor antagonism on interstitial and ultrastructural remodeling of heart in response to a hypercaloric diet.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Collagen; Diet, High-Fat; Losartan | 2019 |
Increased expression of (pro)renin receptor does not cause hypertension or cardiac and renal fibrosis in mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Female; Fibrosis; Heart Ventricles; H | 2014 |